Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-protamine-DNA-mediated antigen delivery.

Dileep Padinjarae Vangasseri1, Su-Ji Han, Leaf Huang

  • 1Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, USA.

Current Drug Delivery
|November 25, 2005
PubMed
Summary

New peptide-based cancer vaccines show promise when combined with adjuvants. Liposome-Protamine-DNA (LPD) nanoparticles enhance antigen delivery, improving vaccine efficiency and potentially reducing dosage requirements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting tumor-associated microbiome: A new aspect of modulating tumor microenvironment for cancer therapy.

Advanced drug delivery reviews·2025
Same author

Flexible and transparent nanohole-patterned films with antibacterial properties against <i>Staphylococcus aureus</i>.

Journal of materials chemistry. B·2024
Same author

Dynamic Covalent Hydrogel as a Single-Dose Vaccine Adjuvant for Sustained Antigen Release and Significantly Elevated Humoral Immunity.

Advanced healthcare materials·2024
Same author

Fusobacterium nucleatum carcinogenesis and drug delivery interventions.

Advanced drug delivery reviews·2024
Same author

Anti-stromal nanotherapeutics for hepatocellular carcinoma.

Journal of controlled release : official journal of the Controlled Release Society·2024
Same author

Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses.

Nature biotechnology·2023

Area of Science:

  • Immunology
  • Nanotechnology
  • Oncology

Background:

  • Novel vaccine systems utilize proteins, peptides, or DNA but often have low efficiency.
  • Adjuvants are frequently incorporated into vaccine formulations to boost immune responses or lower required doses.

Purpose of the Study:

  • To provide an overview of recent advancements in peptide-based cancer vaccine adjuvants.
  • To highlight the role of Liposome-Protamine-DNA (LPD) nanoparticles in antigen delivery for cancer vaccines.

Main Methods:

  • Review of recent literature on peptide-based cancer vaccine adjuvants.
  • Focus on nanoparticle-mediated antigen delivery systems, specifically LPD nanoparticles.

Main Results:

  • Peptide-based vaccines often require adjuvants for optimal performance.

Related Experiment Videos

  • LPD nanoparticles represent a promising strategy for enhancing antigen delivery in cancer vaccines.

    • Conclusions:

    • Adjuvant-enhanced peptide vaccines, particularly those using LPD nanoparticle technology, are a significant area of development in cancer immunotherapy.
    • Further research into LPD nanoparticle-mediated delivery could lead to more effective cancer vaccines.